Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

Fusion Genes Emerge as Key Drivers in Cancer Development

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer development. These genetic alterations result in the creation of hybrid genes with altered functions, often driving tumor progression.

25 Jun 2025

3D Cell Cultures Improve Drug Screening Accuracy but Show Lower Efficacy for Anti-Cancer Drugs

The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.

21 Jun 2024

U of T Researchers Develop Groundbreaking Platform for Protein-Based Disease Treatment

Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins -; a new but largely unrealized approach to the treatment of disease.

25 Mar 2024

Developing a potential drug molecule that targets STAT5

STAT5 has generally been recognized as an enticing cancer target, but after years of research, it was downgraded to the “undruggable” category. Now, scientists at the University of Michigan Rogel Cancer Center have achieved success with a novel approach.

17 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Study targets metabolic pathways to identify sensitivities among cancer cells

Metabolic reprogramming, accepted as a hallmark of cancer, might indicate a vulnerability to be used by targeted cancer therapy.

17 Dec 2021

Protein phosphatase inhibition could contribute to the treatment of cancer, other diseases

The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.

13 Jan 2021

Molecular landscape of myelodysplastic/myeloproliferative neoplasms revealed

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is a group of rare malignancies with overlapping features from myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), that include a variety of diseases depending on their phenotype (hematological and morphological characteristics).

3 Jul 2020

Researchers use genome-wide CRISPR technology to identify leukemia's weakness

A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.

From UC San Diego 21 Apr 2020